New number of shares and votes in Biovitrum AB (publ)

The total number of shares in  Biovitrum AB (publ) as per 30  January
2009 amounts to in total 50,098,782 shares, whereof 49,814,782 common
shares  and  284,000  class  C  shares,  corresponding  to  in  total
49,843,182 votes.  The increase  in the  number of  shares and  votes
results from Biovitrum's asset  purchase agreement entered into  with
Amgen Inc."

For more information please contact:
Biovitrum
Göran Arvidson, CFO
Phone: +46 8 697 23 68

Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com


About Biovitrum
Biovitrum is a Swedish pharmaceutical company. The company markets  a
range  of  specialist  pharmaceuticals  internationally.  Using   its
expertise and experience  Biovitrum takes  scientific innovation  all
the way  to the  market and  to specialist  indication patients  with
significant medical  need. Research  expertise and  capabilities  are
focused on development and  production of biotechnology  therapeutics
within our prioritized  areas of hemophilia,  inflammation/autoimmune
diseases and malabsorption. The company has revenues of approximately
SEK 1.3 billion  and around 500  employees. It is  listed on the  OMX
Nordic  Exchange   in  Stockholm.   For   more  information   go   to
www.biovitrum.com.


Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on January 30, 2009 at
11:30 a.m. CET.